All In Biotech

Drug Trial Radar · NCT02489903

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 139 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

139

Actual

Start

Jun 2015

Primary completion

Dec 6, 2021

Study completion Dec 6, 2021

Sponsor

Lead sponsor
EpicentRx, Inc.Industry
Sponsor type
Industry
First posted
Jul 3, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen. RRx-001 is administered with autologous blood once weekly followed by or in combination with reintroduction of platinum-based doublet therapy.

Conditions

  • Small Cell Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Neuroendocrine Tumors
  • Ovarian Epithelial Cancer

Interventions

  • RRx-001Drug

  • CisplatinDrug

  • EtoposideDrug

  • CarboplatinDrug

  • IrinotecanDrug

  • VinorelbineDrug

  • DoxilDrug

  • GemcitabineDrug

  • TaxaneDrug

  • PaclitaxelDrug

  • Nab-PaclitaxelDrug

  • PemetrexedDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From start of treatment through death for up to 64 months from Start of Treatment.

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Palo Alto, California

  • VA Connecticut Cancer Center

    West Haven, Connecticut

  • Memorial Hospital of South Bend

    South Bend, Indiana

  • Baptist Health

    Lexington, Kentucky

  • Walter Reed National Military Medical Center

    Bethesda, Maryland

  • Henry Ford Allegiance Health

    Jackson, Michigan

  • Washington University

    St Louis, Missouri

  • University of Cincinnati Cancer Institute

    Cincinnati, Ohio

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • West Virginia University

    Morgantown, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.